New pages
Jump to navigation
Jump to search
- 15:23, 25 April 2024 Daprodustat (hist | edit) [1,157 bytes] Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...")
- 21:14, 24 April 2024 Tranexamic (hist | edit) [23,022 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...")
- 21:06, 24 April 2024 Bexagliflozin (hist | edit) [5,887 bytes] Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}")
- 03:47, 21 April 2024 BRENZAVVY- bexagliflozin (hist | edit) [12,281 bytes] Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...")
- 16:30, 19 April 2024 Sparsentan (hist | edit) [8,644 bytes] Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...")
- 19:33, 17 April 2024 SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY (hist | edit) [2,387 bytes] Hafiza Amna Qadeer (talk | contribs) (Created blank page)
- 08:08, 17 April 2024 Elranatamab-bcmm (hist | edit) [32,900 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Palovarotene (hist | edit) [39,234 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Pozelimab-bbfg (hist | edit) [2,443 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Motixafortide (hist | edit) [26,106 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Momelotinib (hist | edit) [34,123 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:06, 17 April 2024 Cipaglucosidase alfa-atga (hist | edit) [38,322 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Etrasimod (hist | edit) [53 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Zilucoplan (hist | edit) [53 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Bimekizumab (hist | edit) [53 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Vamorolone (hist | edit) [53 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Mirikizumab-mrkz (hist | edit) [53 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:03, 17 April 2024 Toripalimab-tpzi (hist | edit) [53 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:02, 17 April 2024 Fruquintinib (hist | edit) [25,648 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
- 07:52, 17 April 2024 Taurolidine, heparin (hist | edit) [9,993 bytes] Edzelco (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")